Plancorp LLC reduced its stake in Eli Lilly And Co (NYSE:LLY) by 14.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,618 shares of the company’s stock after selling 1,612 shares during the period. Plancorp LLC’s holdings in Eli Lilly And Co were worth $1,032,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of LLY. WEALTHFRONT Corp boosted its position in Eli Lilly And Co by 11.6% during the 3rd quarter. WEALTHFRONT Corp now owns 37,008 shares of the company’s stock worth $3,971,000 after buying an additional 3,841 shares during the period. Woodley Farra Manion Portfolio Management Inc. boosted its position in Eli Lilly And Co by 8.3% during the 3rd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 21,341 shares of the company’s stock worth $2,290,000 after buying an additional 1,637 shares during the period. First Republic Investment Management Inc. boosted its position in Eli Lilly And Co by 0.3% during the 3rd quarter. First Republic Investment Management Inc. now owns 359,907 shares of the company’s stock worth $38,621,000 after buying an additional 905 shares during the period. Bailard Inc. acquired a new stake in Eli Lilly And Co during the 3rd quarter worth approximately $277,000. Finally, Highbridge Capital Management LLC acquired a new stake in Eli Lilly And Co during the 3rd quarter worth approximately $2,874,000. Institutional investors own 77.09% of the company’s stock.

Several equities research analysts recently commented on the stock. Citigroup downgraded shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 target price on the stock. in a research report on Sunday. Zacks Investment Research lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday. Guggenheim started coverage on shares of Eli Lilly And Co in a report on Monday, October 8th. They set a “buy” rating for the company. ValuEngine upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a report on Monday, October 8th. Finally, JPMorgan Chase & Co. set a $123.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Friday, October 5th. Ten analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $111.24.

Eli Lilly And Co stock traded down $2.00 during mid-day trading on Wednesday, hitting $116.52. 5,614,286 shares of the stock were exchanged, compared to its average volume of 4,666,741. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. Eli Lilly And Co has a 12 month low of $73.69 and a 12 month high of $119.84. The firm has a market cap of $125.68 billion, a price-to-earnings ratio of 27.22, a PEG ratio of 1.85 and a beta of 0.31.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.05 EPS. As a group, equities research analysts predict that Eli Lilly And Co will post 5.58 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be paid a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 annualized dividend and a dividend yield of 1.93%. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.

In other news, major shareholder Eli & Co Lilly sold 700,000 shares of Eli Lilly And Co stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the sale, the insider now owns 3,148,647 shares in the company, valued at approximately $44,081,058. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Alfonso G. Zulueta sold 6,000 shares of Eli Lilly And Co stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the completion of the sale, the senior vice president now owns 55,224 shares of the company’s stock, valued at approximately $5,870,863.44. The disclosure for this sale can be found here. Insiders sold a total of 2,127,300 shares of company stock valued at $166,973,853 in the last quarter. 0.11% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Eli Lilly And Co (LLY) Shares Sold by Plancorp LLC” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/eli-lilly-and-co-lly-shares-sold-by-plancorp-llc/2662460.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.